What is the half-life of FOXO4-DRI?

FOXO4-DRI has a half-life of ~12-24 hours (estimated due to D-amino acid stability), which is why it's typically administered Twice weekly for defined cycles for optimal therapeutic effect.

How do I reconstitute FOXO4-DRI?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Anti-Ageing

Preclinical

FOXO4-DRI

Also known as: FOXO4-DRI Senolytic, Proxofim

Overview

Key Facts

Primary Goal: A D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells

A D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. By blocking this survival mechanism, FOXO4-DRI selectively triggers apoptosis in senescent cells while leaving healthy cells unaffected — a targeted senolytic approach to reversing age-related cellular deterioration. Half-Life ~12-24 hours (estimated due to D-amino acid stability) Typical Dose 5–20 mg Frequency Twice weekly for defined cycles Cycle Length 2-4 weeks on, extended rest periods (months)

Dosing Information

Half-Life

~12-24 hours (estimated due to D-amino acid stability)

Typical Dose

5–20 mg

Frequency

Twice weekly for defined cycles

Cycle Length

2-4 weeks on, extended rest periods (months)

Administration Routes:

subcutaneousintravenous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

Published in Cell (2017) by de Keizer et al., FOXO4-DRI demonstrated selective clearance of senescent cells in naturally aged mice, resulting in restored fitness, fur density, and renal function. The D-retro-inverso design confers protease resistance and improved bioavailability. While one of the most scientifically compelling senolytic approaches, it remains strictly in preclinical research with no human trials completed. Its large size and synthesis complexity make it one of the most expensive research peptides.